These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 10702556)

  • 21. Antistaphylococcal activity of DX-619, a new des-F(6)-quinolone, compared to those of other agents.
    Bogdanovich T; Esel D; Kelly LM; Bozdogan B; Credito K; Lin G; Smith K; Ednie LM; Hoellman DB; Appelbaum PC
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3325-33. PubMed ID: 16048943
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Staphylococcus aureus mutants isolated via exposure to nonfluorinated quinolones: detection of known and unique mutations.
    Roychoudhury S; Twinem TL; Makin KM; Nienaber MA; Li C; Morris TW; Ledoussal B; Catrenich CE
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3422-6. PubMed ID: 11709318
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Extended spectrum of quinolone resistance, even to a potential latter third-generation agent, as a result of a minimum of two GrlA and two GyrA alterations in quinolone-resistant Staphylococcus aureus.
    Yoon EJ; Lee CY; Shim MJ; Min YH; Kwon AR; Lee J; Choi EC
    Chemotherapy; 2010; 56(2):153-7. PubMed ID: 20407243
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of gyrA, gyrB, grlA and grlB mutations in fluoroquinolone-resistant clinical isolates of Staphylococcus aureus.
    Takahashi H; Kikuchi T; Shoji S; Fujimura S; Lutfor AB; Tokue Y; Nukiwa T; Watanabe A
    J Antimicrob Chemother; 1998 Jan; 41(1):49-57. PubMed ID: 9511037
    [TBL] [Abstract][Full Text] [Related]  

  • 25. GyrA sequence analysis of Staphylococcus aureus and methicillin-resistant S. aureus strains selected, in vitro, for high-level ciprofloxacin resistance.
    Peterson LR; Willard KE; Sinn LM; Fasching CE; Gerding DN
    Diagn Microbiol Infect Dis; 1993; 17(2):97-101. PubMed ID: 7902228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Examination of single and multiple mutations involved in resistance to quinolones in Staphylococcus aureus by a combination of PCR and denaturing high-performance liquid chromatography (DHPLC).
    Hannachi-M'Zali F; Ambler JE; Taylor CF; Hawkey PM
    J Antimicrob Chemother; 2002 Nov; 50(5):649-55. PubMed ID: 12407120
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rapid method for detection of gyrA and grlA mutations in unrelated strains of Staphylococci susceptible and resistant to levofloxacin.
    Messina C; Cafiso V; Campanile F; Santagati M; Stefani S
    New Microbiol; 2001 Oct; 24(4):347-53. PubMed ID: 11718372
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacodynamic modeling of the evolution of levofloxacin resistance in Staphylococcus aureus.
    Campion JJ; Chung P; McNamara PJ; Titlow WB; Evans ME
    Antimicrob Agents Chemother; 2005 Jun; 49(6):2189-99. PubMed ID: 15917512
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between mutations in the coding and promoter regions of the norA genes in 42 unrelated clinical isolates of Staphylococcus aureus and the MICs of norfloxacin for these strains.
    Schmitz FJ; Hertel B; Hofmann B; Scheuring S; Verhoef J; Fluit AC; Heinz HP; Köhrer K; Jones ME
    J Antimicrob Chemother; 1998 Oct; 42(4):561-3. PubMed ID: 9818767
    [No Abstract]   [Full Text] [Related]  

  • 30. Construction of a gyrA plasmid for genetic characterization of fluoroquinolone-resistant Staphylococcus aureus.
    Tankovic J; Duval J; Courvalin P
    FEMS Immunol Med Microbiol; 1994 Jun; 9(1):35-9. PubMed ID: 7920462
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selection of oxacillin resistance in oxacillin-sensitive Staphylococcus aureus through exposure to ciprofloxacin but not piperacillin/tazobactam.
    Evans ME
    Eur J Clin Microbiol Infect Dis; 2002 Aug; 21(8):621-3. PubMed ID: 12226696
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effects of NorA inhibition on the activities of levofloxacin, ciprofloxacin and norfloxacin against two genetically related strains of Staphylococcus aureus in an in-vitro infection model.
    Aeschlimann JR; Kaatz GW; Rybak MJ
    J Antimicrob Chemother; 1999 Sep; 44(3):343-9. PubMed ID: 10511401
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Susceptibility and resistance genes to fluoroquinolones in methicillin-resistant Staphylococcus aureus isolated in 2002.
    Noguchi N; Okihara T; Namiki Y; Kumaki Y; Yamanaka Y; Koyama M; Wakasugi K; Sasatsu M
    Int J Antimicrob Agents; 2005 May; 25(5):374-9. PubMed ID: 15848290
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Levofloxacin selects fluoroquinolone-resistant methicillin-resistant Staphylococcus aureus less frequently than ciprofloxacin.
    Evans ME; Titlow WB
    J Antimicrob Chemother; 1998 Feb; 41(2):285-8. PubMed ID: 9533474
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of the mechanisms of quinolone resistance in clinical isolates of Citrobacter freundii.
    Navia MM; Ruiz J; Ribera A; de Anta MT; Vila J
    J Antimicrob Chemother; 1999 Dec; 44(6):743-8. PubMed ID: 10590274
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance.
    Entenza JM; Que YA; Vouillamoz J; Glauser MP; Moreillon P
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3076-83. PubMed ID: 11600359
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in-vitro activities of ciprofloxacin, sparfloxacin and moxifloxacin against clinical isolates of Staphylococcus aureus.
    Schmitz FJ; Fluit AC; Lückefahr M; Engler B; Hofmann B; Verhoef J; Heinz HP; Hadding U; Jones ME
    J Antimicrob Chemother; 1998 Dec; 42(6):807-10. PubMed ID: 10052906
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Introduction of a norA promoter region mutation into the chromosome of a fluoroquinolone-susceptible strain of Staphylococcus aureus using plasmid integration.
    Kaatz GW; Seo SM; Foster TJ
    Antimicrob Agents Chemother; 1999 Sep; 43(9):2222-4. PubMed ID: 10471568
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DX-619, a novel des-fluoro(6) quinolone manifesting low frequency of selection of resistant Staphylococcus aureus mutants: quinolone resistance beyond modification of type II topoisomerases.
    Strahilevitz J; Truong-Bolduc QC; Hooper DC
    Antimicrob Agents Chemother; 2005 Dec; 49(12):5051-7. PubMed ID: 16304172
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quinolone resistance mutations in the GrlB protein of Staphylococcus aureus.
    Tanaka M; Onodera Y; Uchida Y; Sato K
    Antimicrob Agents Chemother; 1998 Nov; 42(11):3044-6. PubMed ID: 9797253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.